210539-03-0

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

The invention belongs to the field of agricultural bactericidal, insecticidal and acaricidal agents, and relates to a substituted amide compound and an application. The substituted amide compound has a structure as shown in a general formula I in the specification; and in the general formula I, substituents are defined in the specification. The compound provided by the invention has broad-spectrum bactericidal, insecticidal and acaricidal activities, has excellent control effects on diseases like cucumber downy mildew, corn rust, wheat powdery mildew and rice blast, especially has better control effects on the corn rust, also has excellent control effects on aphids and Tetranychus cinnabarinus, and especially can obtain good effects on the Tetranychus cinnabarinus at a low dosage.

The invention discloses a substituted tetrahydroisoquinoline compound and application. The compound has a structure as shown in a general formula I in the specification; and in the general formula I, substituents are defined in the specification. The comp

Provided are a condensed pyridine derivative having a serotonin 5-HT2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT2C receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Tetrahydroquinolinone and tetrahydronaphthyridone cannabinoid receptor ligand compounds and stereoisomers, mixtures of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, and isomorphic crystalline forms the

Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.